Preclinical Evaluation of Juvenile Toxicity

Methods in Molecular Biology

Volumn 691, Issue , 2011, Pages 17-35

  Barrow, Paul C ^a   Barbellion, Stéphane ^b   Stadler, Jeanne ^c  

^a Les Oncins   (France)

^b SANOFI   (France)

^c Toxicology Consulting   (France)

Author keywords

Juvenile animals; Pediatric; Safety testing; Toxicology

Indexed keywords

ADULT; AGING; ANIMAL; ANIMAL MODEL; ARTICLE; BIOASSAY; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED DISORDER; CHILD; DRUG APPROVAL; DRUG EFFECT; DRUG SCREENING; DRUG TOXICITY; EUROPE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; LEGAL ASPECT; MALE; METHODOLOGY; NEUROLOGIC DISEASE; PHYSIOLOGY; SPECIES DIFFERENCE; TOXICITY TESTING; UNITED STATES;

ADULT; AGING; ANIMALS; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CHILD; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; ENDPOINT DETERMINATION; EUROPE; FEMALE; FOLLOW-UP STUDIES; GOVERNMENT REGULATION; HUMANS; MALE; MODELS, ANIMAL; NERVOUS SYSTEM DISEASES; SPECIES SPECIFICITY; TOXICITY TESTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79952201221     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-849-2_2     Document Type: Chapter

References (38)

1. Choonara, I. (2000) Clinical trials of medicines in children: US experience shows how to ensure that treatment of children is evidence based. Br. Med. J. 321, 1093–1094.
2. Conroy, S., McIntyre, J., and Choonara, I. (1999) Unlicensed and off label drug use in neonates. Arch. Dis. Child. 80, F142–F145.
3. Conroy, S., Choonara, I., Impicciatore, P., Mohn, A., Arnell, H., Rane, A., Knoeppel, C., Seyberth, H., Pandolfini, C., Raffaelli, M.P., Rocchi, F., Bonati, M., ‘t Jong, G., de Hoog, M., and van den Anker, J. (2000) Survey of unlicensed and off label drug use in pediatric wards in European countries. Br. Med. J. 320, 79–82.
4. Committee on Drugs, American Academy of Pediatrics. (1995) Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations. Pediatrics 95(2), 286–294.
5. WHO (1986) Principles for evaluating health risks from chemicals during infancy and early childhood: the need for a special approach. International Programme on Chemical Safety. Environmental Health Criteria 59. World Health Organization, Geneva.
6. Guzelian, P.S., Henry, C.J., and Olin, S.S. (1992) Similarities and differences between children and adults: Implications for risk assessment. ILSI Press, Washington, D.C.
7. FDA (1998a) Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Fed. Regist. 63, 66632–66672.
8. FDA (1998b) List of drugs for which additional pediatric information may produce health benefits in the pediatric population. Fed. Regist. 63, 27732–27733.
9. FDA (2005) Draft guidance for industry: How to comply with the pediatric research equity act. September 2005 (http://www. fda.gov/cber/gdlns/pedreseq.pdf).
10. FDA (2007) Should your child be in a clinical trial? http://www.fda.gov/consumer/updates/pediatrictrial101507.html. Consulted 19 May 2008.
11. ICH (2000b) E11: Clinical investigation of medicinal products in the pediatric population. Fed. Regist. 65, 19777–19781.
12. EU (2006) Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 – Official Journal of the European Union. 27 December 2006, pp. L378-1-19.
13. EU (2006) – Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use – Official Journal of the European Union 27 December 2006, pp. L378-20-21.
14. EMEA (2007) European Medicine Agency decision of 3 December 2007 on a class waiver on conditions in accordance with Regulation (EC) 1901/2006 of the European Parliament and of the Council as amended – EMEA/ 551894/2007 P/1/2007.
15. ICH (1994) Step 4 tripartite harmonised guidelines. Detection of toxicity to reproduction for medicinal products, in Proceedings of the second international conference on harmon-isation Orlando (D’Arcy, P.F., and Harron, D.W.G., eds.), Queen’s University: Belfast. pp. 557–578.
16. Barrow, P. (1990) Technical procedures in reproduction toxicology. Laboratory animals handbooks 11. Royal Society of Medicine, London.
17. Baldrick, P. (2004) Developing drugs for pediatric use: A role for juvenile animal studies? Regul. Toxicol. Pharmacol. 39, 381–389.
18. Hurtt, M.E. (2004) Workshop Summary. Juvenile animal studies: Testing strategies and design. Birth Defects Res. B Dev. Reprod. Toxicol. 71(4), 281–288.
19. FDA (2006) Guidance for industry: nonclinical safety evaluation of pediatric drug products, February 2006 (http://www.fda.gov/cder/guidance/5671fnl.htm).
20. EMEA (2008) Guideline on the need for nonclinical testing in juvenile animals on human pharmaceuticals for paediatric indications. Ref. EMEA/CHMP/SWP/169215/2008.
21. ICH (2000a) M3(R1): Maintenance of the ICH guideline on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals.
22. Barrow, P. (2000) Reproductive and developmental toxicology safety studies, in The laboratory rat. (Krinke, G.J., ed.), Academic Press, London, pp. 199–225.
23. NCR3S (2008) Blood sampling microsite. http://www.nc3rs.org.uk/bloodsampling-microsite/page.asp?id=346, consulted 16 May 2008.
24. Barrow, P.C., and Ravel, G. (2005) Immune assessments in developmental and juvenile toxicology: Practical considerations for the regulatory safety testing of pharmaceuticals. Regul. Toxicol. Pharmacol. 43, 35–44.
25. Hurtt, M.E., and Sandler, J.D. (2003) Comparative organ system development: Introduction. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 85.
26. Beckman, D.A., and Feuston, M. (2003) Landmarks in the development of the female reproductive system. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 137–143.
27. Hew, K.W., and Keller, K.A. (2003) Postnatal anatomical and functional development of the heart: A species comparison. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 309–320.
28. Holsapple, M.P., West, L.J., and Landreth, K.S. (2003) Species comparison of anatomical and functional immune system development. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 321–334.
29. Marty, M.S., Chapin, R.E., Parks, L.G., and Thorsrud, B.A. (2003) Development and maturation of the male reproductive system. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 125–136.
30. Walthall, K., Cappon, G.D., Hurtt, M.E., and Zoetis, T. (2005) Postnatal development of the gastrointestinal system: A species comparison. Birth Defects Res. B Dev. Reprod. Toxicol. 74, 132–156.
31. Watson, R.E., DeSesso, J.M., Hurtt, M.E., and Cappon, G.D. (2006) Postnatal growth and morphological development of the brain: A species comparison. Birth Defects Res. B Dev. Reprod. Toxicol. 77, 471–484.
32. Wood, S.L., Beyer, B.K., and Cappon, G.D. (2003) Species comparison of postnatal CNS development: Functional measures. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 391–407.
33. Zoetis, T., Tassinari, M.S., Bagi, C., Walthall, K., and Hurtt, M.E. (2003) Species comparison of postnatal bone growth and development. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 86–110.
34. Zoetis, T., and Hurtt, M.E. (2003) Species comparison of anatomical and functional renal development. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 111–120.
35. Zoetis, T., and Hurtt, M.E. (2003) Species comparison of lung development. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 121–124.
36. Beck, M.J., Padgett, E.L., Bowman, C.J., Wilson, D.T., Kaufman, L.E., Varsho, B.J., Stump, D.G., Nemec, M.D., and Holson, J.F. (2006) Nonclinical juvenile toxicity testing, in Developmental and reproductive toxicology: A practical approach, 2nd ed. (Hood, R. D., ed.), CRC Press, Boca Raton, pp. 263–328.
37. Meyer, J.S. (1998) Behavioral assessment in developmental neurotoxicology, in Handbook of developmental neurotoxicology (Slikker, W., and Chang, L.W., eds.), Academic Press, San Diego, pp. 403–426.
38. Barrow, P. (2007) Toxicology testing for products intended for pediatric populations, in Nonclinical drug safety assessment: Practical considerations for successful registration, (Sietsema, W.K., and Schwen, R., eds.) FDA News, Washington, D.C., pp. 411–440.